Madrigal Pharmaceuticals, Inc.

NASDAQ:MDGL

Biotechnology

Healthcare
$398.08 -0.27%

-$1.33 today

Market cap
$9.25B
Beta
-1.06
P/E (TTM)
-46.9
EPS (TTM)
-$10.66
52W Low $276.67High $615.00

Volume 0.64M

Average 0.31M

MDGL Cash & Equivalents

Cash on hand and highly liquid investments that can be converted to cash almost immediately.

Madrigal Pharmaceuticals, Inc.NASDAQ: MDGL

Cash & Equivalents · Q2 FY2026 · quarter ended Jun 2026

Cash & equivalents rises 57.2% from a year ago

Cash & equivalents stood at $292.73M at the end of Q2 FY2026, up 57.2% from a year earlier and up 26.1% from the prior quarter. Over 3 fiscal years it compounded at -15.7% a year.

Context

  • Cash & equivalents amounted to 23.5% of total assets at the end of Q2 FY2026, up 5.2 pp from a year earlier.
  • Cash & equivalents increased in 2 of the last 3 fiscal years.

What to watch

Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +57.2% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterJun 2026
$292.73M+26.1% QoQ
Last fiscal yearDec 2025
$198.69M+98.7% YoY
Year agoJun 2025
$186.19M+57.2% since
Cash & Equivalents past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+57.2%——
1 year+98.7%——
3-year CAGR-15.7%——
5-year CAGR——
10-year CAGR——

Cash & Equivalents history

USD · from the balance sheet

Latest · FY2025
198.69M USD
Year-over-year change
+98.7%
4-year CAGR
+53.0%

Cash & Equivalents vs competitors

How MDGL compares with its peers on the latest reported figures

  • Peers report in different currencies, so cash & equivalents is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of +57.2% is the 3rd highest of 7, against a peer median of -11.0%.
  • Cash & equivalents amounts to 23.5% of total assets for MDGL, versus a peer median of 36.9%.
MDGL Competitors
Cash & Equivalents for MDGL and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
NAMSNewAmsterdam Pharma Company N.V.Jun 2026$424.15M USD-24.8%+1.6%60.2%
MDGLMadrigal Pharmaceuticals, Inc.Jun 2026$292.73M USD+57.2%-15.7%23.5%
MAZEMaze Therapeutics, Inc.Mar 2026$198.77M USD-32.5%+23.7%47.4%
VKTXViking Therapeutics, Inc.Jun 2026$125.75M USD+271.2%+65.4%24.1%
IVAInventiva S.A.Dec 2025€99.27M EUR+2.8%+4.6%39.9%
ALTAltimmune, Inc.Mar 2026$97.6M USD+98.8%-26.7%29.1%
SGMTSagimet Biosciences Inc.Mar 2026$36.63M USD-43.4%+505.2%34.0%
Peer median (excluding MDGL) —-11.0%+14.2%36.9%

Competitors are the stored peer set for MDGL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents36.27M331.55M99.92M100.02M198.69M
Short-term Investments234.08M27.23M534.22M826.23M784.87M
Net Receivables00053.82M134.48M
Inventory00034.07M74.84M
Other Current Assets02.6M3.15M18.79M52.89M
Total Current Assets271.68M361.37M637.28M1.03B1.25B
Property, Plant & Equipment (Net)1.65M1.2M3.27M4.59M6.44M
Goodwill00000
Intangible Assets0004.73M7.38M
Long-term Investments00000
Tax Assets00000
Other Non-current Assets00000
Total Non-current Assets1.65M1.2M3.27M9.32M13.82M
Total Assets273.33M362.57M640.55M1.04B1.26B
Account Payables21.38M23.83M28.04M43.6M48.88M
Short-term Debt00001.02M
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities6.77M14.86M17.03M34.96M260.39M
Total Current Liabilities76.84M115.89M118.55M169.28M310.29M
Long-term Debt049.29M115.48M117.57M346.61M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities0000(6.73M)
Total Non-current Liabilities387K49.29M116.67M118.59M346.61M
Total Liabilities77.23M165.18M235.21M287.86M656.9M
Common Stock2K2K2K2K2K
Retained Earnings(667.31M)(962.66M)(1.34B)(1.8B)(2.09B)
Accumulated OCI(80K)(32K)468K468K873K
Other Stockholders Equity00000
Minority Interest00000
Total Equity196.11M197.39M405.33M754.38M602.69M
Total Debt797K49.89M117.19M119.57M354.36M
Net Debt(35.47M)(281.66M)17.28M19.55M155.67M

Madrigal Pharmaceuticals, Inc.

NASDAQ:MDGL

Intrinsic Alpha fair value

Locked

Current Price

$398.08

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.